Photo Illustration of the new Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, Victoza and Wegovy. Its a prescription medicine used with a reduced calorie diet and physical activity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images)
UCG/Universal Images Group via Getty Images
New research in the Journal of Clinical Oncology suggests that GLP-1 weight loss medications can lower the risk of cancer development. An observational study involving over 200,000 mammograms of women aged 45 to 80 evaluated breast cancer detection rates. It found that women using GLP-1 medications had a 30% lower likelihood of developing breast cancer compared to those who did not take these drugs.
These medications are not only associated with a reduced risk of developing cancer but also with slowing the progression of existing cancers. A recent study examined over 10,000 patients with early-stage cancer and found that GLP-1 drugs slowed cancer advancement across six tumor types, including colon, breast, liver, and lung cancers. For instance, the progression to stage IV lung cancer was 22.3% in patients not using GLP-1 drugs, compared to just 10% among those who did use them.
While more research is needed to establish a direct causal link between GLP-1 drugs and cancer risk reduction, these findings suggest potential public health benefits. Below are the implications of these findings for public health.
Cancer Risk Reduction
Cancer is the second leading cause of death in the United States, as reported by the CDC. Obesity is linked to at least 13 types of cancer, including those of the breast, colon, liver, and kidney. With around 40% of American adults classified as obese, addressing this condition could significantly lower cancer rates. Public health efforts traditionally focus on cancer screening, tobacco cessation, and lifestyle changes. If further research confirms that GLP-1 drugs can substantially reduce cancer risk, these medications could become a valuable tool in cancer prevention.
Shift In Obesity Perception
Obesity has long been seen as a lifestyle issue linked to diet and activity. However, organizations like the World Health Organization now recognize it as a chronic medical condition that contributes to several health problems, such as diabetes, heart disease, kidney disease, and potentially cancer. Effective obesity treatment could impact metabolic health, potentially influencing heart disease and cancer risk.
GLP-1 drugs work by influencing hormones that regulate weight, insulin levels, and cravings. Further research is needed, but these drugs may also affect metabolic pathways that control inflammation, a known factor in many cancers. Understanding these pathways could enhance knowledge of cancer’s molecular causes.
Caveats
Despite the promising potential of GLP-1 drugs in cancer prevention, most current studies are observational and do not definitively prove that these drugs reduce cancer risk. Randomized controlled trials are necessary to confirm if the observed reductions in cancer risk are substantial and clinically relevant.
Additionally, for these drugs to be used as a public health tool for cancer prevention or treatment, more data is needed on which cancers are most affected by GLP-1s, the duration of therapy required for protection, and whether benefits vary between different GLP-1 medications.
The Future
The growing evidence of the benefits of GLP-1 drugs is compelling. Studies indicate that these medications can reduce the risk of heart attacks, strokes, kidney disease, obstructive sleep apnea, and potentially cancer. If future studies support the initial findings on cancer, these therapies could be pivotal not only in addressing obesity but also in transforming cancer prevention and public health strategies.
